Clinical Trial Search

Primary: Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period — NA; NA weeks

Primary: Time to Confirmed Disease Progression (CDP) — NA; NA weeks — p=0.1442

Primary: Effect on Cerebral Blood Flow in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus — 8.55; 5.12; 5.78; 2.06 Percentage of change in CBF

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase — -0.13; -1.04 units on a…

Primary: Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) — 1.55; 0.80; 0.46; 0.89 units on a scale * year

Primary: Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF). — -0.00168; -0.00392 ratio — p=0.04

Primary: Mean Overall Response Score (ORS) — -0.74; -0.75; -0.64 score on a scale

Primary: Brain Atrophy by MRI — -0.4; -1.3 whole brain percent volume change

Primary: Percentage Change in Whole Brain Volume — 0.288; 0.584 percentage of brain volumen change — p=0.003

Primary: Expanded Disability Status Scale (EDSS) Plus — 17; 17 Participants — p=1.0

Primary: Change in Mobility: Timed 25 Foot Walk — -0.39; -0.30 feet per second — p=0.51

Primary: Rate of Change in Brain Parenchymal Fraction — 0.107; -0.355 percentage of change in brain volume — p=0.346

Primary: Number of Participants Classified as Upper Limb Responders on the 9 Hole Peg Test (9HPT) — 4; 3; 58; 59 Participants

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events

Primary: The Brief Repeatable Battery of Rao — 42.09; 35.5 Correct words — p=0.028

Primary: Absolute Percent Change in Written Naming (Trained Items) — 39.4; 28.4; 33.1; 20.0 absolute percent change

Primary: Percent Brain Volume Change (PBVC) From Baseline to Week 48 Using a Repeated Measures ANCOVA Model — -0.454; -0.438 percentage change from baseline — p=0.903

Primary: Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS) — 11.97; 12.04 months — p=0.0026

Primary: Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate — 0.501; 0.389; 0.319 relapses per year — p=0.0001

Primary: Change in Fatigue Severity Scale (FSS)-9 Score — 4.20; 3.99; 2.82; 4.25 units on a scale

Primary: Changes in Language as Measured Through the Boston Naming Test (BNT) — 1.8; 2.5; 0.063; 0.5 Items

Primary: Proportion of Research Cohort Subjects Referred Into a Clinical Trial or Offered Treatment With an Appropriate Second-line Therapy. — 178 Participants

Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…

Primary: Number of Participants With Treatment-emergent Adverse Events — 18 Participants

Primary: Connectivity Measures of the Left TGd, 55b, and STV Parcellations at Baseline and Post-treatment — -.06; .03; -.01 correlation

Primary: Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab — -1232.97; -1169.13; -1008.13; -931.83 pg/mL

Primary: Percentage of Participants With Infusion-related Reaction (IRR) Treated With 600 mg IV Ocrelizumab — 0 Percentage of Participants

Primary: Kinematics — 15.5; 10 degrees